This content is machine translated Hypertrophic cardiomyopathies (HCM) How do myosin inhibitors perform in different HCM phenotypes? Cardiac myosin inhibitors have been developed as a targeted therapeutic option for modulating sarcomere function. While in clinical trials in obstructive hypertrophic cardiomyopathy they brought about a greater improvement in...…
View Post 15 min This content is machine translated Cardiovascular health in women Hormonal contraception, stress disorders and cardiovascular risk in women Cardiovascular disease is the leading cause of death in women, and stress-related psychiatric disorders are considered cardiovascular risk factors in their own right. Hormonal contraceptives, which are used by around...…
View Post 8 min This content is machine translated Obesity treatment: new study data Incretin mimetics for comorbidities such as type 2 diabetes, ASCVD, HF, OSAS Lifestyle-related measures are the basic framework in the treatment of overweight and obesity. However, in order to achieve and maintain the target weight, accompanying pharmacological or surgical measures are usually...…
View Post 14 min This content is machine translated Cardio-oncology When the heart pays for cancer treatment Recent studies show that cardiovascular mortality can become the leading cause of death in cancer survivors over the years. New data on ICI myocarditis, landmark cardioprotection trials and the first...…
View Post 12 min This content is machine translated Anticoagulation after cerebral hemorrhage with atrial fibrillation What PRESTIGE-AF answers – and what remains unanswered According to study results, direct oral anticoagulation (DOAC) can effectively prevent ischemic strokes in survivors of intracerebral hemorrhage with atrial fibrillation. However, the results also show a relevant increase in...…
View Post 15 min This content is machine translated MASH and heart health The underestimated cardiovascular threat Metabolic-associated steatohepatitis (MASH) was long considered a purely hepatic problem. Today, data from large clinical trials and registries clearly show that cardiovascular disease is the most common cause of death...…
View Post 11 min This content is machine translated Sleep apnea and cardiovascular diseases Breathless through the night 936 million people affected worldwide, a cardiovascular risk profile that complements traditional risk factors and new pharmacological treatment options: Current evidence from 2024-2026 paints a clearer picture of a link...…
View Post 6 min This content is machine translated Acute pulmonary embolism: new AHA/ACC guideline Practical recommendations for risk-stratified triage In February 2026, the American Heart Association (AHA) and the American College of Cardiology (ACC) published a new guideline on the assessment and treatment of acute pulmonary embolism in cooperation...…
View Post 13 min This content is machine translated Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology Lp(a): The underestimated risk factor before the turning point One in five people worldwide has a genetically elevated lipoprotein(a) – and knows nothing about it. Unlike LDL cholesterol, this independent, causally significant risk factor cannot be significantly influenced by...…
View Post 14 min This content is machine translated Heart failure and type 2 diabetes Oral semaglutide and cardiac decompensation in type 2 diabetes The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF –...…
View Post 12 min This content is machine translated Current evidence, risk classes and new counseling options Hormonal contraception and cardiovascular risk Over 247 million women worldwide use hormonal contraception – the majority with combined oral contraceptives (COCs). This prevalence is accompanied by an ongoing medical responsibility: venous thromboembolism, ischemic strokes and...…
